Preclinical characterization of azviii-7-18, a novel paullone derivative for the treatment of ALS

The Trustees of Columbia University in New York City will receive $809,262 from the Department of the Army Medical Command under a Project Grant award to support preclinical characterization of AZVIII-7-18, a novel Paullone derivative for the treatment of ALS. The funding period is from July 1, 2022 to June 30, 2024.

The award is being made through the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research aimed at transforming military and public health care through innovative medical solutions for battlefield injuries and other conditions. Specifically, the funding will allow Columbia University researchers to conduct preclinical studies to characterize a new compound that may have therapeutic potential for treating amyotrophic lateral sclerosis. The place of performance for the research is New York, NY.